ClinicalTrials.gg
Enrolling by invitationNCT07950540Updated Nov 20, 2026

Proactive Therapy of Acute Radiation-induced Skin Injury in Head and Neck Cancer

A Phase 2 interventional study of Reactive tacrolimus and Reactive Mometasone in Radiation Dermatitis Acute, sponsored by Poznan University of Medical Sciences. Enrolling by invitation at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Poznan University of Medical Sciences · Phase 2, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 1 year 8 months after the study started (first participant enrolled Mar 2025, registered Nov 2026).
Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Almost all patients who receive radiotherapy for head and neck cancer develop a skin reaction in the treated area, known as acute radiation-induced skin injury (aRISI), also called acute radiation dermatitis. Mild reactions cause redness, itching and peeling; severe reactions can be painful, may interrupt cancer treatment, and reduce quality of life. The most commonly used preventive creams are topical glucocorticosteroids (steroids). These can help, but prolonged use of topical steroids carries its own risks, such as skin thinning and small visible blood vessels, which is a particular concern on the delicate skin of the head and neck during a six- to seven-week course of radiotherapy.

Topical calcineurin inhibitors, such as tacrolimus, are steroid-free anti-inflammatory creams that have been used safely for more than 20 years in other inflammatory skin conditions (for example, atopic dermatitis), including long-term "proactive" application to prevent flares. Because radiation skin injury and these conditions share similar inflammatory mechanisms, tacrolimus is a biologically plausible, steroid-sparing alternative for preventing or treating aRISI. To date, however, it has not been tested for this purpose in a randomized trial.

This single-center, randomized trial in adults undergoing radiotherapy (alone or combined with chemotherapy or other systemic treatment) for head and neck cancer evaluates whether topical tacrolimus can prevent or delay aRISI and whether it is as effective as, and better tolerated than, topical steroids. Participants are randomly assigned to one of four groups that differ in the cream applied preventively ("proactively") from the first day of radiotherapy and the cream applied to treat an established reaction ("reactively"):

Group 1 (standard of care): no preventive cream; mometasone (a potent steroid) if a reaction develops.

Group 2: preventive hydrocortisone (a mild steroid); mometasone reactively. Group 3: no preventive cream; tacrolimus reactively. Group 4: preventive tacrolimus; tacrolimus reactively.

All participants also follow a standardized skin-care routine (emollient and sun protection). The preventive cream is applied twice weekly from the first day of radiotherapy until two weeks after it ends; the reactive cream is applied once daily once a reaction appears. Skin reactions are graded regularly using standard scales (RTOG and CTCAE). For safety, the study cream is stopped if a severe (grade 3) reaction develops, and the patient is kept under close monitoring and managed according to current recommendations.

The main outcome is the time from the start of radiotherapy to the first visible skin reaction (grade 1 or higher). Other outcomes include the time to more severe reactions, the maximum severity reached, how quickly reactions progress once they start, treatment side effects, and patient-reported quality of life. By directly comparing a steroid-free calcineurin inhibitor with topical steroids and standard care, the study aims to provide the first randomized evidence on whether tacrolimus can safely delay or reduce radiation-induced skin injury in head and neck cancer, and to guide the design of larger confirmatory trials.

02

Conditions studied

  • Radiation Dermatitis Acute
03

In context

Lead sponsor

Poznan University of Medical Sciences is the lead sponsor of 152 studies on the registry; 42 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years or older,
  • confirmed head and neck cancer,
  • Scheduled to receive radiotherapy as primary or postoperative treatment (given alone, as chemoradiotherapy with cisplatin, or in combination with immunotherapy or small-molecule agents).

Exclusion criteria

Exclusion Criteria:

  • Skin changes or dermatological complications of oncological treatment not characteristic of aRISI,
  • Any pre-existing dermatosis in the head and neck region,
  • Use of topical glucocorticosteroids or a topical calcineurin inhibitor (tacrolimus or pimecrolimus) in the irradiated area within 1 month before enrollment,
  • Radiotherapy for a non-head-and-neck .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Active comparator
    no proactive agent; reactive mometasone furoate 0.1%.

    No proactive agent, reactive mometasone fuorate 0.1%, cream, applied once daily to the irradiated area

    Drug: Reactive Mometasone

  • Experimental
    proactive hydrocortisone acetate 10 mg/g; reactive mometasone fuorate 0.1%

    proactive hydrocortisone acetate cream 10 mg/g, applied twice weekly to the irradiated area, reactive mometasone fuorate 0.1%, cream, applied once daily to the irradiated area

    Drug: Reactive Mometasone · Drug: Proactive hydrocortisone

  • Experimental
    no proactive agent; reactive tacrolimus 0.1%.

    no proactive therapy, reactive tacrolimus 0.1% ointment, applied once daily to the irradiated area

    Drug: Reactive tacrolimus

  • Experimental
    proactive tacrolimus 0.1%; reactive tacrolimus 0.1%.

    proactive tacrolimus 0.1% ointment, applied twice weekly to the irradiated area, reactive tacrolimus 0.1% ointment, applied once daily to the irradiated area

    Drug: Reactive tacrolimus · Drug: Proactive tacrolimus

Interventions

  • DrugReactive tacrolimus

    Reactive tacrolimus 0.1% ointment, applied once daily to the irradiated area

  • DrugReactive Mometasone

    Reactive mometasone fuorate cream 0.1%, applied once daily to the irradiated area

  • DrugProactive tacrolimus

    Proactive tacrolimus 0.1% ointment, applied twice weekly to the irradiated area

  • DrugProactive hydrocortisone

    Proactive hydrocortisone acetate 10 mg/g, cream, applied twice weekly to the irradiated area

06

What researchers measure

Primary outcomes

  1. Time from start of radiotherapy to first acute radiation-induced skin injury (aRISI), RTOG grade >=1

    Time (in days) from day 1 of radiotherapy to the first appearance of RTOG grade \>=1 aRISI. Skin reactions are graded daily by the investigators using the Radiation Therapy Oncology Group (RTOG) acute radiation morbidity scoring criteria for skin (grade range 0 to 4; higher grade indicates a worse, more severe reaction).

    Time frame: From Day 1 of radiotherapy through 2 weeks after completion of radiotherapy (an average of approximately 9 weeks); participants not reaching the grade are censored at that time.

Secondary outcomes

  1. Time from start of radiotherapy to RTOG grade 2 aRISI

    Time (in days) from day 1 of radiotherapy to the first RTOG grade 2 aRISI, graded daily by the investigators using the Radiation Therapy Oncology Group (RTOG) acute radiation morbidity scoring criteria for skin (grade range 0 to 4; higher grade indicates a worse, more severe reaction). Computed only among participants reaching grade 2.

    Time frame: From Day 1 of radiotherapy through 2 weeks after completion of radiotherapy (an average of approximately 9 weeks); participants not reaching grade 2 are censored.

  2. Time from start of radiotherapy to RTOG grade 3 aRISI

    Time (in days) from day 1 of radiotherapy to the first RTOG grade 3 aRISI, graded daily by the investigators using the Radiation Therapy Oncology Group (RTOG) acute radiation morbidity scoring criteria for skin (grade range 0 to 4; higher grade indicates a worse, more severe reaction). Per protocol, grade 3 is the maximum on-study grade (study preparation discontinued at grade 3). Computed only among participants reaching grade 3.

    Time frame: From Day 1 of radiotherapy through 2 weeks after completion of radiotherapy (an average of approximately 9 weeks); participants not reaching grade 3 are censored.

  3. Maximum aRISI severity (RTOG grade)

    Maximum aRISI reaction grade per participant, assessed daily by the investigators using the Radiation Therapy Oncology Group (RTOG) acute radiation morbidity scoring criteria for skin. Scale range: grade 0 to 4; higher scores indicate a worse (more severe) outcome. Per protocol, grade 3 is the maximum on-study grade.

    Time frame: From Day 1 of radiotherapy through 2 weeks after completion of radiotherapy (an average of approximately 9 weeks).

  4. Progression intervals between successive RTOG grades, by reactive agent

    Time interval (in days) between successive RTOG grades (grade 1 to 2, grade 2 to 3, and grade 1 to 3), compared between reactive agents. Grades assessed daily using the Radiation Therapy Oncology Group (RTOG) acute radiation morbidity scoring criteria for skin (grade range 0 to 4; higher indicates a more severe reaction). Each interval is computed only among participants who reached both grades of the pair.

    Time frame: From Day 1 of radiotherapy through 2 weeks after completion of radiotherapy (an average of approximately 9 weeks).

  5. Number of participants with treatment-emergent adverse events

    Number (and proportion) of participants with treatment-emergent adverse events (e.g., bacterial skin infection, rosacea-like eruption, skin atrophy, telangiectasia), assessed by clinical assessment and photographic documentation at each on-treatment visit.

    Time frame: From Day 1 of radiotherapy through 2 weeks after completion of radiotherapy (an average of approximately 9 weeks).

  6. Health-related quality of life measured by the Dermatology Life Quality Index (DLQI)

    Patient-reported quality of life measured with the Dermatology Life Quality Index (DLQI), a 10-item questionnaire completed per questionnaire instructions. Total score range: 0 to 30; higher scores indicate a worse outcome (greater impairment of health-related quality of life).

    Time frame: Assessed weekly from baseline (Day 1) through completion of radiotherapy (an average of approximately 7 weeks).

  7. Skin-related quality of life measured by the Skindex-16 (SD-16)

    Patient-reported skin-related quality of life measured with the Skindex-16 (SD-16), a 16-item questionnaire scored overall and in three domains (Symptoms, Emotions, Functioning), completed per questionnaire instructions. Score range: 0 to 100; higher scores indicate a worse outcome (greater burden).

    Time frame: Assessed weekly from baseline (Day 1) through completion of radiotherapy (an average of approximately 7 weeks).

  8. Disease severity measured by the Physician's Global Assessment (PGA)

    Clinician-rated overall severity of the skin reaction measured with the Physician's Global Assessment (PGA). Scale range: 0 to 4 (e.g., 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 = severe); higher scores indicate a worse (more severe) outcome. Assessed weekly by the physician.

    Time frame: Assessed weekly from baseline (Day 1) through completion of radiotherapy (an average of approximately 7 weeks).

  9. Disease severity measured by the Investigator's Global Assessment (IGA)

    Investigator-rated overall severity of the skin reaction measured with the Investigator's Global Assessment (IGA). Scale range: 0 to 4 (e.g., 0 = clear to 4 = severe); higher scores indicate a worse (more severe) outcome. Assessed weekly by the investigator.

    Time frame: Assessed weekly from baseline (Day 1) through completion of radiotherapy (an average of approximately 7 weeks).

07

Study locations

1 site
  • Department of Dermatology, Poznan University of Medical Sciences
    Poznan, Poland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2025 (actual). Primary completion is estimated for Nov 2026, 20 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2026
First posted
Nov 20, 2026
StartActual
Mar 1, 2025
Primary completionEst.
Nov 30, 2026
CompletionEst.
Nov 1, 2028
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07950540
Responsible party
Sponsor
First posted
Nov 20, 2026
Start date
Mar 1, 2025
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 1, 2028 (estimated)
Last update
Nov 20, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion